Pharmacoeconomics

Alkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific Conferences

Retrieved on: 
星期二, 五月 14, 2024
Patient, ALKS, Pharmacoeconomics, Health, Bipolar I disorder, ARISTADA, APA, American Psychiatric Association, International Society, Safety, Mental Health Awareness Month, Efficacy, Research, Psychiatry, Olanzapine, Schizophrenia, ASCP, Annual general meeting, Pharmaceutical industry

DUBLIN, May 14, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the presentation of research related to its psychiatry franchise products—LYBALVI® (olanzapine and samidorphan) and ARISTADA® (aripiprazole lauroxil)—at four scientific conferences this spring. These meetings take place during Mental Health Awareness Month in May, an important moment in the year to raise awareness about mental health conditions, support people living with these complex diseases, and honor the work of healthcare providers. The meetings include:

Key Points: 
  • DUBLIN, May 14, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the presentation of research related to its psychiatry franchise products—LYBALVI® (olanzapine and samidorphan) and ARISTADA® (aripiprazole lauroxil)—at four scientific conferences this spring.
  • "These data from across our psychiatry product franchise demonstrate our commitment to expanding the body of evidence for our medicines and advancing understanding of their real-world impact.
  • Highlights of the upcoming presentations include:
    Findings from an international, multicenter, phase 3, open-label extension study assessing the long-term safety, tolerability and durability of treatment effect of LYBALVI in patients who received up to four years of treatment.
  • Results from a real-world study of treatment patterns and healthcare resource utilization among patients with schizophrenia before and after initiating ARISTADA using the ARISTADA INITIO® initiation regimen.

Alkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific Conferences

Retrieved on: 
星期二, 五月 14, 2024
Patient, ALKS, Pharmacoeconomics, Health, Bipolar I disorder, ARISTADA, APA, American Psychiatric Association, International Society, Safety, Mental Health Awareness Month, Efficacy, Research, Psychiatry, Olanzapine, Schizophrenia, ASCP, Annual general meeting, Pharmaceutical industry

DUBLIN, May 14, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the presentation of research related to its psychiatry franchise products—LYBALVI® (olanzapine and samidorphan) and ARISTADA® (aripiprazole lauroxil)—at four scientific conferences this spring. These meetings take place during Mental Health Awareness Month in May, an important moment in the year to raise awareness about mental health conditions, support people living with these complex diseases, and honor the work of healthcare providers. The meetings include:

Key Points: 
  • DUBLIN, May 14, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the presentation of research related to its psychiatry franchise products—LYBALVI® (olanzapine and samidorphan) and ARISTADA® (aripiprazole lauroxil)—at four scientific conferences this spring.
  • "These data from across our psychiatry product franchise demonstrate our commitment to expanding the body of evidence for our medicines and advancing understanding of their real-world impact.
  • Highlights of the upcoming presentations include:
    Findings from an international, multicenter, phase 3, open-label extension study assessing the long-term safety, tolerability and durability of treatment effect of LYBALVI in patients who received up to four years of treatment.
  • Results from a real-world study of treatment patterns and healthcare resource utilization among patients with schizophrenia before and after initiating ARISTADA using the ARISTADA INITIO® initiation regimen.

Verona Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on: 
星期四, 五月 9, 2024
FDA, International Society, Inflammation, Bromide, EDT, Chronic obstructive pulmonary disease, Risk, Safety, Food, Conference call, Research, Conference, Information technology, Disease, PDUFA, Patient, Pharming, Marketing, VRNA, Pharmacoeconomics, Growth, BST, COPD, Pharmaceutical industry

LONDON and RALEIGH, N.C., May 09, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a biopharmaceutical company focused on respiratory diseases, announces its financial results for the first quarter ended March 31, 2024, and provides a corporate update.

Key Points: 
  • PDUFA Target Action Date for Ensifentrine of June 26, 2024
    Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST
    LONDON and RALEIGH, N.C., May 09, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a biopharmaceutical company focused on respiratory diseases, announces its financial results for the first quarter ended March 31, 2024, and provides a corporate update.
  • If approved, the Company intends to launch ensifentrine in the US market in the third quarter of 2024.
  • Verona Pharma will host an investment community webcast and conference call at 9:00 a.m. EDT / 2:00 p.m. BST on Thursday, May 9, 2024, to discuss the first quarter 2024 financial results and the corporate update.
  • An electronic copy of the first quarter 2024 results press release will also be made available today on the Company’s website.

BioCryst Presents New Real-world Evidence Showing Significant Reductions in Healthcare Resource Utilization Among Patients with HAE Following Initiation of ORLADEYO® (berotralstat)

Retrieved on: 
星期四, 五月 9, 2024
University, International Society, Poster, BioCryst Pharmaceuticals, LTP, MD, History, Documentation, Hereditary angioedema, Patient, Medicine, HRU, HAE, Pharmacoeconomics, Disease, Pharmaceutical industry

“The data presented here represent the first documentation that prescribing ORLADEYO significantly reduces healthcare resource utilization.

Key Points: 
  • “The data presented here represent the first documentation that prescribing ORLADEYO significantly reduces healthcare resource utilization.
  • This outcome provides a compelling argument that ORLADEYO, which is known to be effective in reducing HAE morbidity, is also a cost-effective strategy for patient management.
  • The poster detailed findings from a retrospective real-world study that featured analysis of administrative claims data of patients with HAE in the United States.
  • We look forward to reporting additional real-world evidence that highlights the benefits associated with long-term prophylaxis with ORLADEYO,” said Dr. William Sheridan, chief development officer and interim chief medical officer of BioCryst.

Komodo Health & Partners Present 33 Real-World Evidence Research Studies at ISPOR 2024

Retrieved on: 
星期一, 五月 6, 2024
Technology, Health, Venture Capital, Professional Services, Artificial Intelligence, Oncology, Other Science, Mental Health, Research, Software, Health Technology, Science, COVID-19, Clinical Trials, Komodo, University of Washington, Lennox–Gastaut syndrome, FDA, Public, University, Target, International Society, RWE, Pregnancy, Policy, AI, Prevalence, Colorectal cancer, Myriad Genetics, LGS, Chronic inflammatory demyelinating polyneuropathy, Neutropenia, CRC, Conference, Workflow, REMS, Genetics, Schizophrenia, Takeda Pharmaceutical Company, Mental health, Neurology, RWD, MPH, Patient, Hypertension, Epilepsy, Gestational age, Standard of care, Stillbirth, Pharmacoeconomics, ZS, Merck, ZS Associates, Breast cancer, Mitigation, Pharmaceutical industry

Komodo Health today announced the publication of 33 new health economics and outcomes research (HEOR) studies using its Healthcare Map and AI-powered technology platform.

Key Points: 
  • Komodo Health today announced the publication of 33 new health economics and outcomes research (HEOR) studies using its Healthcare Map and AI-powered technology platform.
  • The studies, to be featured at the 2024 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Global Conference, shed light on important disease trends spanning women’s health, oncology, mental health, hypertension, neurology, and more.
  • Komodo Health researchers studied the differences in patient outcomes for pregnant women who continued or discontinued the use of antidepressants during pregnancy.
  • Komodo Health researchers analyzed whether the COVID-19 pandemic exacerbated inequities in breast cancer care through its impact on breast cancer staging and HCRU.

Evidation Shares Real-World Data on GLP-1 Use and Social Determinants of Health at ISPOR 2024

Retrieved on: 
星期一, 五月 6, 2024
Software, Data Analytics, Internet, General Health, Health, Data Management, Professional Services, Technology, Online, International Society, Abstract, Weight loss, Doctor of Philosophy, Transport, Life, Exercise, Diet, Data collection, Face, Social, Pharmacoeconomics, Walking, Quality of life

Current GLP-1 users were more likely to have private insurance and to be targeting more significant weight loss.

Key Points: 
  • Current GLP-1 users were more likely to have private insurance and to be targeting more significant weight loss.
  • Social Determinants of Health Associated with Delayed Medical Care in an Online Health Community (#EPH199) illuminates critical and persistent barriers to timely medical care from a survey of 203,486 US adults.
  • Almost 5 million Members strong, Evidation rewards users for engaging in healthy activities and contributing to health research.
  • Using Evidation, health researchers can comprehensively characterize and measure disease onset and progression, treatment impact, quality of life, and social determinants of health across diverse populations over longer observation periods.

DistillerSR Launches Online Courseware for the Pragmatic Application of Scientifically Validated AI to Literature Reviews

Retrieved on: 
星期二, 五月 7, 2024
Part, International Society, AI, Collection, Conference, Research, Literature, Booth, Pharmacoeconomics, Inc., Organization, Health, Medical device

OTTAWA, ON, May 7, 2024 /PRNewswire/ -- DistillerSR® Inc., the market leader in AI-enabled literature review automation software and creator of DistillerSR™, today announced the availability of a new AI training module targeted at medical research professionals conducting literature reviews.  Part of an extensive online portal of training and certification modules, called DistillerSR Learn,  Demystifying AI is a training course designed to help literature review practitioners understand AI terminology, the technology that underpins it, its current limitations, and how to use AI successfully in the preparation of regulatory submissions.  The course complements other DistillerSR training content on the platform's core AI capabilities, which help customers dramatically reduce time to market for medical products and health care guidelines.

Key Points: 
  • The course complements other DistillerSR training content on the platform's core AI capabilities, which help customers dramatically reduce time to market for medical products and health care guidelines.
  • "Since 2016, DistillerSR has used fully integrated scientifically validated AI to further automate the literature review process," said Peter O'Blenis, CEO, DistillerSR Inc. "Our accessible and current AI courseware will help research professionals place into context the current AI market hype while providing a pragmatic, responsible approach to the application of AI in critical health research and regulatory submissions.
  • As the AI market rapidly evolves, we will continue to update our courseware offerings to support the ongoing introduction of new AI capabilities for DistillerSR."
  • DistillerSR's training programs are designed to help researchers improve their ability to conduct faster, more accurate literature reviews.

BioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024

Retrieved on: 
星期一, 五月 6, 2024
Cancer, International Society, Multiple myeloma, TEL, CD34, Value in Health, Filgrastim, Doctor of Philosophy, ASCT, BioLineRx, Patient, MPH, HSC, Pharmacoeconomics, Professional, G-CSF, Nursing

TEL AVIV, Israel, May 6, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that new economic model data will be presented on APHEXDA® (motixafortide) for CD34+ hematopoietic stem cell (HSC) mobilization in patients with multiple myeloma at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) – The Professional Society for Health Economics and Outcomes Research – 2024 conference, taking place May 5-8, 2024, in Atlanta, Georgia.

Key Points: 
  • TEL AVIV, Israel, May 6, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that new economic model data will be presented on APHEXDA® (motixafortide) for CD34+ hematopoietic stem cell (HSC) mobilization in patients with multiple myeloma at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) – The Professional Society for Health Economics and Outcomes Research – 2024 conference, taking place May 5-8, 2024, in Atlanta, Georgia.
  • Autologous stem cell transplantation (ASCT) is part of the standard of care treatment paradigm for multiple myeloma and prolongs survival for patients with this cancer type.1 Historically, depending on induction regimens and mobilization strategies, approximately 50% to 75% of patients required more than one apheresis session to collect a target number of cells.2,3 Uncertainty in stem cell mobilization and the possible need for multiple apheresis sessions may result in psychological and logistical burden on patients, in addition to financial and operational inefficiencies for apheresis centers.
  • The data are expected to be published in Value in Health, Volume 27, Issue 6, S1 (June 2024.)
  • Presenter: Jeffrey R Skaar, PhD, Trinity Life Sciences, New York, NY and Jennifer L Lessor, MPH, BioLineRx USA, Inc., Waltham, MA
    The new economic model data to be presented at ISPOR 2024 builds on the evaluation of APHEXDA for CD34+ HSC mobilization in patients with multiple myeloma in apheresis center operations.

Cognito Therapeutics Announces Presentation at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2024 Meeting

Retrieved on: 
星期一, 四月 29, 2024
Medical Devices, Health, Neurology, Research, Science, Biotechnology, Alzheimer's disease, Humanism, MCI, International Society, Literature, Patient, Caregiver, Cognito, Pharmacoeconomics, Therapy, Quality of life, Ageing, Pharmaceutical industry

Cognito Therapeutics , a leader in technology-based therapeutic interventions for neurodegenerative diseases, announced today a poster presentation at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2024 Meeting, held May 5-8 in Atlanta, GA.

Key Points: 
  • Cognito Therapeutics , a leader in technology-based therapeutic interventions for neurodegenerative diseases, announced today a poster presentation at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2024 Meeting, held May 5-8 in Atlanta, GA.
  • The presented research is a targeted literature review of the clinical, humanistic, and economic burden of Alzheimer’s Disease (AD).
  • This surge underscores the pressing need for improved understanding and management of this debilitating neurological disease, given the current limitations in treatment options.
  • A targeted literature review was conducted to gain insights into the clinical, humanistic, and economic burden of mild-to-moderate AD, including mild cognitive impairment (MCI).

MindMed to Present at Upcoming May Medical Conferences

Retrieved on: 
星期四, 四月 25, 2024
Mental Health, Health, Other Health, General Health, Clinical Trials, Pharmaceutical, Biotechnology, APA, Congress, American Psychiatric Association, MindMed, Epidemiology, Medicine, GAD, Pharmacoeconomics, Lysergic acid diethylamide

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it will present detailed results from its phase 2b study of MM120 in Generalized Anxiety Disorder (GAD), as well as multiple presentations describing the epidemiology and growing burden of GAD at two upcoming medical conferences:

Key Points: 
  • Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it will present detailed results from its phase 2b study of MM120 in Generalized Anxiety Disorder (GAD), as well as multiple presentations describing the epidemiology and growing burden of GAD at two upcoming medical conferences:
    American Psychiatric Association (APA) 2024 Congress, New York, NY
    Title: Rapid and Durable Response to a Single Dose of MM120 (Lysergide) in Generalized Anxiety Disorder: A Dose-Optimization Study
    International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2024, Atlanta, GA
    Posters will be available on MindMed’s Company website following the conferences.